Nanomaterials in Healthcare: Regulatory Aspects and Safety Perspectives

The integration of nanotechnology into the healthcare system has led to the emergence of nanomedicine that offers transformative potential in advanced diagnostics, targeted drug delivery, and tissue engineering. However, the unique properties of nanoparticles, which enable their widespread application, also allow them to infiltrate living systems and ecosystems through various pathways. This has raised significant concerns about their safety, toxicity, and environmental impact. These risks underscore the urgent need for robust regulatory frameworks and comprehensive guidelines to guarantee nanomedicine’s safe development and use. International agencies such as the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), Organization for Economic Cooperation and Development (OECD), National Institute for Food and Drug Control (NIFDC) in China, and the Therapeutic Goods Association (TGA) in Australia are actively working on establishing effective risk assessment frameworks and regulatory landscapes for nanomaterials. These initiatives aim to evaluate potential hazards, exposure risks, and long-term impacts associated with nanoparticles. This chapter highlights the need for collaborative international efforts to develop standardized regulations, enabling the safe and sustainable integration of nanomaterials into healthcare while minimizing risks to human health and the environment.